Business · 1 sources covering this

Divi's Labs Shares In Focus: Citi Reaffirms 'Buy' With Rs 11,700 Target On Oral Wegovy Upside

Citi said Divi's has an integrated and cost-efficient peptide manufacturing platform, which could provide an advantage as demand for peptide-based therapies expands.

Share:WhatsApp X Reddit Facebook LinkedIn

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

NDTVCenter·1h ago
Divi's Labs Shares In Focus: Citi Reaffirms 'Buy' With Rs 11,700 Target On Oral Wegovy Upside
Citi said Divi's has an integrated and cost-efficient peptide manufacturing platform, which could provide an advantage as demand for peptide-based therapies expands.
Read at NDTV →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://hindustansphere.com/embed/cluster/995f4465323d8a78741690d8381fd027a2f6afec"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="Divi's Labs Shares In Focus: Citi Reaffirms 'Buy' With Rs 11,700 Target On Oral Wegovy Upside"></iframe>

Divi's Labs Shares In Focus: Citi Reaffirms 'Buy' With Rs 11,700 Target On Oral Wegovy Upside

How 1 sources are covering this

Divi's Labs Shares In Focus: Citi Reaffirms 'Buy' With Rs 11,700 Target On Oral Wegovy Upside

More from Business

Explainer: What’s behind PM Narendra Modi’s Chintan Shivir?

Can Trump legally ban media outlets from White House? DOJ says yes — here's what happens next

Samsung, LG Face Inquiry In India For Alleged Tariff Underpayment On Premium TV Parts: Report

Rupee falls 12 paise to close at 95.74 against U.S. dollar

Reader

Trust & legal

Across the network